{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:03:56Z","timestamp":1768507436383,"version":"3.49.0"},"posted":{"date-parts":[[2023,8,27]]},"group-title":"Bioengineering","reference-count":78,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Bispecific antibodies are an important tool for the management and treatment of acute leukemias. Advances in genome-engineering have enabled the generation of human plasma cells that secrete therapeutic proteins and are capable of long-term\n                  <jats:italic>in vivo<\/jats:italic>\n                  engraftment in humanized mouse models. As a next step towards clinical translation of engineered plasma cells (ePCs) towards cancer therapy, here we describe approaches for the expression and secretion of bispecific antibodies by human plasma cells. We show that human ePCs expressing either fragment crystallizable domain deficient anti-CD19 x anti-CD3 (blinatumomab) or anti-CD33 x anti-CD3 bispecific antibodies mediate T cell activation and direct T cell killing of specific primary human cell subsets and B-acute lymphoblastic leukemia or acute myeloid leukemia cell lines\n                  <jats:italic>in vitro<\/jats:italic>\n                  . We demonstrate that knockout of the self-expressed antigen, CD19, boosts anti-CD19 bispecific secretion by ePCs and prevents self-targeting. Further, anti-CD19 bispecific-ePCs elicited tumor eradication\n                  <jats:italic>in vivo<\/jats:italic>\n                  following local delivery in flank-implanted Raji lymphoma cells. Finally, immunodeficient mice engrafted with anti-CD19 bispecific-ePCs and autologous T cells potently prevented\n                  <jats:italic>in vivo<\/jats:italic>\n                  growth of CD19\n                  <jats:sup>+<\/jats:sup>\n                  acute lymphoblastic leukemia in patient-derived xenografts. Collectively, these findings support further development of ePCs for use as a durable, local delivery system for the treatment of acute leukemias, and potentially other cancers.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>Key points<\/jats:title>\n                  <jats:list list-type=\"bullet\">\n                    <jats:list-item>\n                      <jats:p>Using gene editing, we engineered human plasma cells that secrete functional bispecifics to target leukemia cells expressing CD19 or CD33<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>Engineered plasma cells secreting bispecifics suppress patient-derived leukemia in immunodeficient mice<\/jats:p>\n                    <\/jats:list-item>\n                  <\/jats:list>\n                <\/jats:sec>","DOI":"10.1101\/2023.08.24.554523","type":"posted-content","created":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T11:55:10Z","timestamp":1693137310000},"source":"Crossref","is-referenced-by-count":4,"title":["Human plasma cells engineered to secrete bispecifics drive effective\n                  <i>in vivo<\/i>\n                  leukemia killing"],"prefix":"10.64898","author":[{"given":"Tyler F.","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parnal","family":"Narvekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Asher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Camp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri R.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023083102100532000_2023.08.24.554523v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.196"},{"issue":"11","key":"2023083102100532000_2023.08.24.554523v1.2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2023083102100532000_2023.08.24.554523v1.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"2023083102100532000_2023.08.24.554523v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609783"},{"key":"2023083102100532000_2023.08.24.554523v1.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0612"},{"issue":"10","key":"2023083102100532000_2023.08.24.554523v1.6","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1177\/1060028020988411","article-title":"A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions","volume":"55","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2023083102100532000_2023.08.24.554523v1.7","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0405-4"},{"key":"2023083102100532000_2023.08.24.554523v1.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-109762"},{"key":"2023083102100532000_2023.08.24.554523v1.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007732"},{"issue":"7","key":"2023083102100532000_2023.08.24.554523v1.10","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","article-title":"Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations","volume":"36","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2023083102100532000_2023.08.24.554523v1.11","doi-asserted-by":"crossref","first-page":"e895","DOI":"10.1016\/j.clml.2021.06.022","article-title":"Clinical Outcomes of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System","volume":"21","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2023083102100532000_2023.08.24.554523v1.12","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0133-6"},{"key":"2023083102100532000_2023.08.24.554523v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.11.012"},{"issue":"1","key":"2023083102100532000_2023.08.24.554523v1.14","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1038\/s41467-022-33787-8","article-title":"Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo","volume":"13","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"2023083102100532000_2023.08.24.554523v1.15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41419-020-03187-1","article-title":"Engineering of \u03b1-PD-1 antibody-expressing long-lived plasma cells by CRISPR\/Cas9-mediated targeted gene integration","volume":"11","year":"2020","journal-title":"Cell Death Dis"},{"issue":"7","key":"2023083102100532000_2023.08.24.554523v1.16","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00262-021-03101-4","article-title":"Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies","volume":"71","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2023083102100532000_2023.08.24.554523v1.17","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13520"},{"key":"2023083102100532000_2023.08.24.554523v1.18","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aax0644"},{"key":"2023083102100532000_2023.08.24.554523v1.19","unstructured":"Huang D , Tran JT , Olson A , et al. Vaccine Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B cells."},{"key":"2023083102100532000_2023.08.24.554523v1.20","doi-asserted-by":"crossref","unstructured":"Voss JE , Gonzalez-Martin A , Andrabi R , et al. Reprogramming the antigen specificity of B cells using genome-editing technologies. eLife. 2019;8.","DOI":"10.7554\/eLife.42995"},{"key":"2023083102100532000_2023.08.24.554523v1.21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190287"},{"issue":"1","key":"2023083102100532000_2023.08.24.554523v1.22","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1038\/s41467-020-19649-1","article-title":"Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion","volume":"11","year":"2020","journal-title":"Nat Commun"},{"key":"2023083102100532000_2023.08.24.554523v1.23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189991"},{"key":"2023083102100532000_2023.08.24.554523v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/40540"},{"key":"2023083102100532000_2023.08.24.554523v1.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066092"},{"key":"2023083102100532000_2023.08.24.554523v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3964"},{"key":"2023083102100532000_2023.08.24.554523v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/nri1886"},{"key":"2023083102100532000_2023.08.24.554523v1.28","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830160206"},{"key":"2023083102100532000_2023.08.24.554523v1.29","doi-asserted-by":"crossref","unstructured":"Marchand T , Pinho S . Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities. Front Immunol. 2021;12:775128.","DOI":"10.3389\/fimmu.2021.775128"},{"issue":"6","key":"2023083102100532000_2023.08.24.554523v1.30","doi-asserted-by":"crossref","first-page":"108733","DOI":"10.1016\/j.celrep.2021.108733","article-title":"Plasma cell dynamics in the bone marrow niche","volume":"34","year":"2021","journal-title":"Cell Rep"},{"key":"2023083102100532000_2023.08.24.554523v1.31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6010022"},{"key":"2023083102100532000_2023.08.24.554523v1.32","doi-asserted-by":"publisher","DOI":"10.1101\/2022.08.25.505190"},{"issue":"12","key":"2023083102100532000_2023.08.24.554523v1.33","doi-asserted-by":"crossref","first-page":"9466","DOI":"10.1128\/jvi.71.12.9466-9474.1997","article-title":"Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells","volume":"71","year":"1997","journal-title":"J Virol"},{"issue":"1","key":"2023083102100532000_2023.08.24.554523v1.34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2023083102100532000_2023.08.24.554523v1.35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.2022016772","article-title":"Avoiding fratricide: a T-ALL order","volume":"140","year":"2022","journal-title":"Blood"},{"key":"2023083102100532000_2023.08.24.554523v1.36","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025726"},{"key":"2023083102100532000_2023.08.24.554523v1.37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020458"},{"key":"2023083102100532000_2023.08.24.554523v1.38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"2023083102100532000_2023.08.24.554523v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.09.032"},{"key":"2023083102100532000_2023.08.24.554523v1.40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10557"},{"key":"2023083102100532000_2023.08.24.554523v1.41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.8.4397"},{"issue":"8","key":"2023083102100532000_2023.08.24.554523v1.42","first-page":"1746","article-title":"Rational drug combinations with CDK4\/6 inhibitors in acute lymphoblastic leukemia","volume":"107","year":"2022","journal-title":"Haematologica"},{"key":"2023083102100532000_2023.08.24.554523v1.43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415448"},{"key":"2023083102100532000_2023.08.24.554523v1.44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694356"},{"key":"2023083102100532000_2023.08.24.554523v1.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"2023083102100532000_2023.08.24.554523v1.46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760"},{"key":"2023083102100532000_2023.08.24.554523v1.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.016"},{"key":"2023083102100532000_2023.08.24.554523v1.48","doi-asserted-by":"crossref","unstructured":"Topp M , Feuchtinger T . Management of Hypogammaglobulinaemia and B-Cell Aplasia. Springer; 2022.","DOI":"10.1007\/978-3-030-94353-0_28"},{"issue":"4","key":"2023083102100532000_2023.08.24.554523v1.49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"2023083102100532000_2023.08.24.554523v1.50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4564"},{"key":"2023083102100532000_2023.08.24.554523v1.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152"},{"issue":"5","key":"2023083102100532000_2023.08.24.554523v1.52","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.ymthe.2018.03.001","article-title":"A Rapamycin-Activated Caspase 9-Based Suicide Gene","volume":"26","year":"2018","journal-title":"Mol Ther"},{"key":"2023083102100532000_2023.08.24.554523v1.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0065-5"},{"key":"2023083102100532000_2023.08.24.554523v1.54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629527"},{"key":"2023083102100532000_2023.08.24.554523v1.55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320"},{"key":"2023083102100532000_2023.08.24.554523v1.56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-555169"},{"key":"2023083102100532000_2023.08.24.554523v1.57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501761"},{"key":"2023083102100532000_2023.08.24.554523v1.58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01901-w"},{"key":"2023083102100532000_2023.08.24.554523v1.59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40231"},{"issue":"3","key":"2023083102100532000_2023.08.24.554523v1.60","doi-asserted-by":"crossref","first-page":"e0229170","DOI":"10.1371\/journal.pone.0229170","article-title":"CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells","volume":"15","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"2023083102100532000_2023.08.24.554523v1.61","doi-asserted-by":"crossref","first-page":"e0002622","DOI":"10.1128\/jvi.00026-22","article-title":"Persistence of Virus-Specific Antibody after Depletion of Memory B Cells","volume":"96","year":"2022","journal-title":"J Virol"},{"key":"2023083102100532000_2023.08.24.554523v1.62","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw151.007"},{"issue":"3","key":"2023083102100532000_2023.08.24.554523v1.63","doi-asserted-by":"crossref","first-page":"e33534","DOI":"10.1371\/journal.pone.0033534","article-title":"Mice deficient in CD38 develop an attenuated form of collagen type II-induced arthritis","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"2023083102100532000_2023.08.24.554523v1.64","doi-asserted-by":"crossref","unstructured":"Papazoglou D , Ysebaert L , Ioannou N , et al. S141: ELICITING ANTI-TUMOR T CELL ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH BISPECIFIC ANTIBODY-BASED COMBINATION THERAPY. HemaSphere. 2022;6:42.","DOI":"10.1097\/01.HS9.0000843456.05456.f5"},{"issue":"3","key":"2023083102100532000_2023.08.24.554523v1.65","first-page":"148","article-title":"Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"35","year":"2010","journal-title":"P T"},{"issue":"5","key":"2023083102100532000_2023.08.24.554523v1.66","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"2023083102100532000_2023.08.24.554523v1.67","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023083102100532000_2023.08.24.554523v1.68","doi-asserted-by":"crossref","unstructured":"Abdallah N , Kumar SK . Daratumumab in untreated newly diagnosed multiple myeloma. Ther Adv Hematol. 2019;10:2040620719894871.","DOI":"10.1177\/2040620719894871"},{"issue":"4","key":"2023083102100532000_2023.08.24.554523v1.69","first-page":"1193","article-title":"Bi38-3 is a novel CD38\/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma","volume":"106","year":"2021","journal-title":"Haematologica"},{"key":"2023083102100532000_2023.08.24.554523v1.70","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"issue":"1","key":"2023083102100532000_2023.08.24.554523v1.71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/jfmpc.jfmpc_578_19","article-title":"Trends in FDA drug approvals over last 2 decades: An observational study","volume":"9","year":"2020","journal-title":"J Family Med Prim Care"},{"issue":"8","key":"2023083102100532000_2023.08.24.554523v1.72","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/GIM.0b013e318133fb1b","article-title":"The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease","volume":"9","year":"2007","journal-title":"Genet Med"},{"issue":"3","key":"2023083102100532000_2023.08.24.554523v1.73","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MBC.0000000000000885","article-title":"Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B","volume":"31","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"2023083102100532000_2023.08.24.554523v1.74","first-page":"CD009354","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme\u00ae) for treating mucopolysaccharidosis type I","volume":"6","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2023083102100532000_2023.08.24.554523v1.75","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00956.x"},{"key":"2023083102100532000_2023.08.24.554523v1.76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02581.x"},{"key":"2023083102100532000_2023.08.24.554523v1.77","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.9.896"},{"key":"2023083102100532000_2023.08.24.554523v1.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.05.027"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.08.24.554523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:08:00Z","timestamp":1768453680000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.08.24.554523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":78,"URL":"https:\/\/doi.org\/10.1101\/2023.08.24.554523","relation":{},"subject":[],"published":{"date-parts":[[2023,8,27]]},"subtype":"preprint"}}